Botulinum Toxin A Treatment of Raynaud's Phenomenon: A Review

Iorio, Matthew L.; Masden, Derek L.; Higgins, James P.

doi:10.1016/j.semarthrit.2011.07.006

Cited by 93 publications

(79 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In clinical practice, BoNTA is used as a vasodilator in treating Raynaud's phenomenon. In a study by Neumeister et al 15 , BoNTA was injected into patients suffering from this condition, with pain and necrotic lesions at the finger extremities 22,23 . After 60 days, all ulcers healed, and 84% of the patients presented improved vascular flow in their hands.…”

mentioning

confidence: 99%

Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats

et al. 2015

View full text Add to dashboard Cite

PURPOSE:To investigate the effect of Botulinum toxin A (BoNTA) on skin flap viability in healthy, tobacco-exposed and diabetic rats. METHODS:Ninety male Wistar rats (250-300g) were randomly divided into six groups: control+saline (C1), control+BoNTA (C2), tobacco-exposed+saline (T1), tobacco-exposed+BoNTA (T2) diabetes+saline (D1) and diabetes+BoNTA (D2). A dorsal cutaneous flap (3×10cm) was performed. Survival area and total area of the flaps were measured. Lumen diameter, external arterial diameter and lumen/wall thickness ratio were recorded. RESULTS:Survival area increased in control group with BoNTA injection compared with control animals injected with saline (C2 x C1; 0.9±0.1 vs 0.67±0.15, p= 0.001). A similar result was found in diabetes group injected with BontA (D2 x D1; 0.97±0.2 vs 0.61±0.24, p=0.018). No difference was observed in skin flap viability in tobacco-exposed groups (T2 x T1; 0.74±0.24 vs 0.64±0.21, p=0.871).Lumen diameter (p= 0.004), external arterial diameter (p = 0.0046,) and lumen/wall thickness ratio (p= 0.003) were increased in diabetes+BoNTA-treated animals. This effect was not observed in control or in tobacco-exposed groups. CONCLUSIONS:Botulinum toxin A increased skin flap viability in control and diabetic rats on the seventh post-operative day.Increased lumen diameter, external arterial diameter, and lumen/wall thickness ratio were observed in the diabetes+BoNTA group.BoNTA had no effect in the tobacco-exposed group on the seventh postoperative day.

show abstract

mentioning

confidence: 99%

Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Most of these studies are case series (Liu, 2006;Heckmann et al, 2002;Kossintseva et al, 2011;Iorio et al, 2012;Serri et al, 2013) , one is randomized controlled trial (Neumeister, 2010) and two case reports (Neumeister et al, 2009;Fregene et al, 2009) (Table 3). In all of these studies the patients were presented with chronic ischemic hand pain, ulceration and loss of function.…”

Section: Raynaud Syndromementioning

confidence: 99%

Botulinum toxin: Non cosmetic and off-label dermatological uses

Alghamdi

Alghanemy

Joharji

et al. 2015

Journal of Dermatology & Dermatologic Surgery

View full text Add to dashboard Cite

Botulinum toxin (BT-A) is a neurotoxin which is produced by the Gram-positive anaerobic bacterium Clostridium botulinum. The efficacy of Botulinum toxin in treating hyperhidrosis and the glabellar lines is well known and FDA approved.Because BT-A inhibits the release of acetylcholine and many other neurotransmitters such as norepinephrine and substance P at the level of nerve ending, this toxin has been used to treat a lot of dermatological disorders which are thought to be triggered by these neurotransmitters.In this article we are discussing the medical off-label uses of BT-A in dermatology.ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.

show abstract

“…However, it is an option and can be used in complicated and severe cases. It should be noted that botulinum toxin locally injected is reported in uncontrolled case series to be helpful [ 5 ]. It is an option in cases not responding to other traditional agents (see Chap.…”

Section: Indications For Drug Therapymentioning

confidence: 99%

“…5 ). There are several case series published suggesting benefi t in treating RP and ischemic digital ulcers [ 5 ]. There are no studies comparing Botox to placebo and it is an expensive treatment option.…”

Section: Botulium Toxin a Botoxmentioning

confidence: 99%

Drug Treatment of Raynaud’s Phenomenon

Pope

2014

Raynaud’s Phenomenon

View full text Add to dashboard Cite

Botulinum Toxin A Treatment of Raynaud's Phenomenon: A Review

Cited by 93 publications

References 15 publications

Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats

Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats

Botulinum toxin: Non cosmetic and off-label dermatological uses

Drug Treatment of Raynaud’s Phenomenon

Contact Info

Product

Resources

About